MENU

CNSP Stock Tickeron detected bullish Stock Pattern: Triangle Symmetrical Top CNSP on October 22, 2024, netting in a 26.37% gain over 1 week

A.I.dvisor
at Tickeron.com
Loading...
+26.37% Gain from a Successful pattern Triangle Symmetrical Top
CNSP - CNS Pharmaceuticals Inc
Tickeron
Ticker: CNSP
Company: CNS Pharmaceuticals
Gain: +26.37%
Confirmed: 10/22/24
Succeeded: 10/22/24
Total length: 8 days
On October 14, 2024, A.I.dvisor detected a Triangle Symmetrical Top Pattern (Bullish) for CNS Pharmaceuticals Inc (CNSP, $0.12). On October 22, 2024, A.I.dvisor confirmed the Bullish pattern, setting a target price of $0.17. On October 22, 2024, CNSP reached the target price resulting in a +2 for traders who took a long position in the stock.

CNSP in downward trend: price dove below 50-day moving average on November 22, 2024

CNSP moved below its 50-day moving average on November 22, 2024 date and that indicates a change from an upward trend to a downward trend. In of 31 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNSP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 59 cases where CNSP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on December 17, 2024. You may want to consider a long position or call options on CNSP as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CNSP just turned positive on December 11, 2024. Looking at past instances where CNSP's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CNSP advanced for three days, in of 189 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.852) is normal, around the industry mean (14.556). P/E Ratio (0.000) is within average values for comparable stocks, (87.563). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.739). CNSP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (256.215).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CNSP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CNSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2100 West Loop South
Phone
+1 800 946-9185
Employees
5
Web
https://www.cnspharma.com